首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.

导出 OA

翻译打印收藏纠错

第一作者： Yoonha,Choi

第一单位： Genentech, Inc., South San Francisco, California.

作者： Yoonha,Choi ^[1] ; Neekesh V,Dharia ^[1] ; Tomi,Jun ^[1] ; Julie,Chang ^[1] ; Stephanie,Royer-Joo ^[1] ; Kenneth K,Yau ^[2] ; Zoe J,Assaf ^[1] ; Junko,Aimi ^[1] ; Smruthy,Sivakumar ^[3] ; Meagan,Montesion ^[3] ; Adrian,Sacher ^[4] ; Patricia,LoRusso ^[5] ; Jayesh,Desai ^[6] ; Jennifer L,Schutzman ^[1] ; Zhen,Shi ^[1] ; and the GO42144 study group

作者单位： Genentech, Inc., South San Francisco, California. ^[1] Hoffmann-La Roche Limited, Mississauga, Canada. ^[2] Foundation Medicine, Boston, Massachusetts. ^[3] Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.;Department of Medicine, University of Toronto, Toronto, Canada.;Department of Immunology, University of Toronto, Toronto, Canada. ^[4] Yale Cancer Center, Yale University, New Haven, Connecticut. ^[5] Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. ^[6]